Pfizer: a phase I clinical study conducted with Immutep


(CercleFinance.com) – The Australian biotech Immutep announced on Tuesday that it would start a phase I clinical study in bladder cancer, in collaboration with the German Merck KGaA and the American Pfizer.

This trial, which should begin in the first half of 2023, aims to assess the efficacy and safety of the combination between efti, Immutep’s lead candidate, with avelumab, the immunotherapy developed by its two partners.

The study, which plans to recruit up to 30 patients, will take place in Germany.

Urothelial carcinoma – or bladder cancer – is expected to affect 81,180 people this year in the United States and lead to the death of about 17,100 people.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.


Twitter


Facebook


LinkedIn


E-mail





Source link -85